IL132278A0 - Treatment of central nervous system disorders with selective estrogen receptor modulators - Google Patents

Treatment of central nervous system disorders with selective estrogen receptor modulators

Info

Publication number
IL132278A0
IL132278A0 IL13227898A IL13227898A IL132278A0 IL 132278 A0 IL132278 A0 IL 132278A0 IL 13227898 A IL13227898 A IL 13227898A IL 13227898 A IL13227898 A IL 13227898A IL 132278 A0 IL132278 A0 IL 132278A0
Authority
IL
Israel
Prior art keywords
treatment
nervous system
central nervous
estrogen receptor
receptor modulators
Prior art date
Application number
IL13227898A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL132278A0 publication Critical patent/IL132278A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13227898A 1997-04-09 1998-04-07 Treatment of central nervous system disorders with selective estrogen receptor modulators IL132278A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4311797P 1997-04-09 1997-04-09
PCT/US1998/007024 WO1998045287A1 (fr) 1997-04-09 1998-04-07 Traitement de troubles du systeme nerveux central avec des modulateurs selectifs de recepteurs d'estrogenes

Publications (1)

Publication Number Publication Date
IL132278A0 true IL132278A0 (en) 2001-03-19

Family

ID=21925589

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13227898A IL132278A0 (en) 1997-04-09 1998-04-07 Treatment of central nervous system disorders with selective estrogen receptor modulators

Country Status (19)

Country Link
US (2) US6077852A (fr)
EP (1) EP0986556A4 (fr)
JP (1) JP2001518898A (fr)
KR (1) KR20010006219A (fr)
CN (1) CN1260792A (fr)
AU (1) AU733421B2 (fr)
BR (1) BR9809389A (fr)
CA (1) CA2286455A1 (fr)
EA (1) EA002360B1 (fr)
HU (1) HUP0002031A3 (fr)
ID (1) ID27986A (fr)
IL (1) IL132278A0 (fr)
NO (1) NO994901L (fr)
NZ (2) NZ514146A (fr)
PL (1) PL336701A1 (fr)
TR (1) TR199902700T2 (fr)
TW (1) TW479056B (fr)
WO (1) WO1998045287A1 (fr)
ZA (1) ZA982877B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
CN1305343A (zh) * 1998-06-16 2001-07-25 伊莱利利公司 提高乙酰胆碱水平的方法
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
JP2002518329A (ja) 1998-06-16 2002-06-25 イーライ・リリー・アンド・カンパニー アセチルコリンレベルを増加させる方法
US6087378A (en) * 1998-10-13 2000-07-11 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
AU6335600A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
AU6335500A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
SK286346B6 (en) * 2000-05-08 2008-07-07 Lilly Co Eli Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
EP1757291A3 (fr) * 2000-05-08 2009-07-15 Eli Lilly & Company Formulations stabilisées de 6-hydroxy-3-(4- 2-(pipéridin-1-yl)éthoxyphénoxy)-2-(4-methoxyphényl) benzo(b)thiophène et sels de ces composés
CN1268624C (zh) * 2000-10-20 2006-08-09 伊莱利利公司 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩盐酸盐的新晶形
CA2681478A1 (fr) * 2007-03-16 2008-09-25 Eli Lilly And Company Procede et intermediaires pour preparer l'arzoxifene
EA017385B1 (ru) 2007-10-16 2012-12-28 Репрос Терапьютикс Инк. Применение транс-кломифена для снижения концентрации глюкозы в сыворотке
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
JP2015508825A (ja) 2012-02-29 2015-03-23 レプロス セラピューティクス インコーポレイティド アンドロゲン欠乏症を治療するための併用療法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN104829568B (zh) * 2015-05-12 2017-03-01 广州中医药大学 一种2‑苯基‑苯骈五元杂环类化合物及其衍生物的医药应用
CN104829569B (zh) * 2015-05-12 2017-04-26 广州中医药大学 一种2‑苯基‑苯骈五元杂环类化合物及其衍生物的应用
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
CA3087528C (fr) 2016-09-15 2024-01-30 Arvinas, Inc. Derives d'indole en tant qu'agents de degradation des recepteurs des oestrogenes
CN111454248A (zh) 2016-12-01 2020-07-28 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
AU2018211975B2 (en) 2017-01-26 2022-05-26 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
CN112839646A (zh) * 2018-08-16 2021-05-25 G1治疗公司 用于治疗医学疾病的苯并噻吩雌激素受体调节剂

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3293263A (en) * 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3320271A (en) * 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
DE1300575B (de) * 1965-05-21 1969-08-07 Bristol Myers Co Benzo[b]thiophene
US3394125A (en) * 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4117128A (en) * 1976-08-03 1978-09-26 Smithkline Corporation Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
GB8705174D0 (en) * 1987-03-05 1987-04-08 Ici Plc Heterocyclic compounds
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5389670A (en) * 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5439931A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US5512296A (en) * 1994-08-22 1996-04-30 Eli Lilly And Company Methods for inhibiting neuronal damage
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
PL182493B1 (pl) * 1995-02-28 2002-01-31 Lilly Co Eli Nowe pochodne benzotiofenu, nowe związki pośrednie i sposób wytwarzania nowych pochodnych benzotiofenu oraz środek farmaceutyczny
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
TR199902700T2 (xx) 2000-06-21
KR20010006219A (ko) 2001-01-26
AU733421B2 (en) 2001-05-17
CA2286455A1 (fr) 1998-10-15
TW479056B (en) 2002-03-11
ZA982877B (en) 1999-10-04
NZ500175A (en) 2001-10-26
BR9809389A (pt) 2002-03-19
EP0986556A4 (fr) 2001-03-21
US6077852A (en) 2000-06-20
NO994901L (no) 1999-12-09
HUP0002031A3 (en) 2003-01-28
WO1998045287A1 (fr) 1998-10-15
HUP0002031A2 (hu) 2001-06-28
EP0986556A1 (fr) 2000-03-22
US20020013342A1 (en) 2002-01-31
NO994901D0 (no) 1999-10-08
EA199900913A1 (ru) 2000-04-24
NZ514146A (en) 2001-09-28
ID27986A (id) 2001-05-03
JP2001518898A (ja) 2001-10-16
PL336701A1 (en) 2000-07-03
AU7104998A (en) 1998-10-30
EA002360B1 (ru) 2002-04-25
CN1260792A (zh) 2000-07-19

Similar Documents

Publication Publication Date Title
IL132278A0 (en) Treatment of central nervous system disorders with selective estrogen receptor modulators
AU8769098A (en) System for treating patients with anxiety disorders
EP1140086A4 (fr) N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
AP2001002308A0 (en) Glucocorticoid receptor modulators
AU2423697A (en) System for treating patients with anxiety disorders
PL323587A1 (en) Gene changing-over system including edisone receptor
EP0971588A4 (fr) Nouveaux modulateurs de recepteurs de cannabinoides
HK1018272A1 (en) Substituted pyridylmethylpiperazine and piperidinederivatives, their preparation and their use for treating central nervous system (cns) disorders
HK1034712A1 (en) Aryylpiperazines having activity at the serotonin 1a receptor
PL350679A1 (en) Derivatives of 1-arenosulphonyl-2-arylpyrolydine and piperidine for treating central nervous system disorders
AU2384500A (en) Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
ZA967944B (en) Substituted cyclohexylamines as central nervous system agents
AU4674797A (en) Phenylalaninol derivatives for the treatment of central nervous system disorders
ZA979060B (en) Receptor selective BNP
EP1011330A4 (fr) Regeneration d'axones dans le systeme nerveux central
PL335307A1 (en) Atropoisomers of 3-heteroaryl-4(3h)-quinazolynes for treating neurodegenerative and traumatic states of central nervous system
IL122557A0 (en) Cytoplasmic modulators of integrin regulation/signaling
IL132279A0 (en) Prevention of breast cancer with selective estrogen receptor modulators
GB9618300D0 (en) Glutamate receptor modulators and the treatment of psychiatric disorders
EP0832124A4 (fr) Recepteur d'amines humaines
HUP0103994A3 (en) Method of stimulating prosaposin receptor activity
HK1040933A1 (zh) N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用
AU2003204221A1 (en) Dipyridoimidazolderivatives useful in treating central nervous system disorders
EP1007064A4 (fr) Regeneration de nerfs dans le systeme nerveux central
IL121597A0 (en) Novel optically pure amines for the treatment of central nervous system disorders